Yahoo
Morningstar

Morningstar

•

Oct 30, 2026

Incyte Corporation: Incyte Earnings: Opzelura Settlement and Latarcibart Improve Outlook Ahead of Jakafi Patent Loss

Symbols

INCY

Sector(s)

Healthcare

Rating

Current Price

120.39

Fair Value

Economic Moat

Stewardship

Summary

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade
Mobilize your Website
View Site in Mobile | Classic
Share by: